リバーロキサバンの世界市場

リバーロキサバンの世界市場は2030年までに224億米ドルに達する見込み

2024年に163億米ドルと推定されるリバーロキサバンの世界市場は、2024年から2030年にかけてCAGR 5.5%で成長し、2030年には224億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである心房細動適応症は、CAGR 7.2%を記録し、分析期間終了時には90億米ドルに達すると予測されます。深部静脈血栓症治療薬の成長率はCAGR 4.0%と推定されます。

米国市場は44億米ドル、中国はCAGR9.0％で成長すると予測

米国のリバーロキサバン市場は2024年に44億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに46億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の「リバーロキサバン」市場- 主要動向と促進要因のまとめ

リバーロキサバンが抗凝固療法の要として台頭している理由とは？

直接第Xa因子阻害薬に属する経口抗凝固薬であるリバーロキサバンは、血栓塞栓症の治療と予防に革命をもたらしています。ワルファリンのような従来のビタミンK拮抗薬に代わる、より利便性の高い抗凝固薬として開発されたリバーロキサバンは、予測可能な薬物動態、固定用量、最小限の食事や薬物相互作用により、患者のアドヒアランスを大幅に改善します。非弁膜症性心房細動（AF）における脳卒中予防、深部静脈血栓症（DVT）、肺塞栓症（PE）の治療、整形外科手術後の予防などの適応で広く使用されています。世界の高齢化と心血管疾患の増加により、対象となる患者層は劇的に拡大しています。さらに、心房細動とその合併症に対する認識の高まりは、早期診断と長期抗凝固療法の必要性につながっています。リバーロキサバンの臨床的有効性と安全性は、実臨床におけるエビデンスによって引き続き裏付けられており、また、現在進行中の直接比較試験では、他のNOAC（非ビタミンK拮抗経口抗凝固薬）と比較して良好な転帰が示されています。日常的な凝固モニタリングが不要で、ワルファリンと比較して頭蓋内出血のリスクが低いという使用の簡便性から、臨床医の間で好んで使用されています。さらに、1日1回の投与という利便性が、1日2回のレジメンを必要とする特定の競合薬と異なる点であり、長期使用例におけるコンプライアンスの向上を支えています。

特許ライフサイクルとジェネリック医薬品は市場構造にどのような影響を与えているか？

主要市場における特許満了が近づくにつれ、競合情勢は大きく変化しています。イグザレルト（R）（バイエルが開発し、ジョンソン・エンド・ジョンソンと共同販売）のようなブランド品は、長年にわたり高価値地域での独占権を享受してきました。しかし、ジェネリック医薬品の参入が間近に迫り、また現在も進行中であることから、価格ダイナミクスが破壊され、アクセシビリティが高まることが予想されます。インド、中国、ブラジルなどのメーカーは、新たに開拓された市場を活用するため、ジェネリック医薬品の生産拡大に向けた準備を進めています。生物学的に同等なジェネリック医薬品の導入は、特にコストに敏感な公衆衛生システムにおいて、治療費の削減につながると期待されています。FDAやEMAなどの規制機関は、優先順位の高いジェネリック医薬品に対してファスト・トラック・プロセスを確立し、発売スケジュールを早めています。これは患者や支払者に利益をもたらす一方で、先発医薬品メーカーにとっては市場シェアを維持する上での課題となります。これに対応するため、先発品メーカーは適応症の拡大、合剤治療、デジタル患者支援プラットフォームに投資しています。さらに、米国、EU、APAC地域では、償還モデルの進化により、段階的な価格戦略が構築されつつあり、企業は地域や支払者の構造に応じてマーケティングや販売活動を調整する必要に迫られています。イノベーション・ライフサイクル・マネジメントとジェネリック医薬品競争の相互作用が、市場の価格弾力性と数量成長を形成すると思われます。

どのような臨床動向と治療拡大が市場の可能性を高めるか？

リバーロキサバンの役割は、主要な適応症にとどまらず、より広範な心血管疾患や血栓塞栓症に拡大しつつあります。最近の承認や臨床試験では、急性冠症候群（ACS）や末梢動脈疾患（PAD）の二次予防、特に糖尿病や腎機能障害などの合併症を有する患者における使用が注目されています。リバーロキサバンは、従来の抗凝固薬では出血リスクが高いがん関連血栓症においても有用であることが、新たなエビデンスによって裏付けられています。また、高リスク患者の心血管イベントを予防するために、抗血小板薬と併用したリバーロキサバンの第III相試験がいくつか行われています。病院から在宅への移行において、非経口抗凝固療法よりも経口抗凝固療法が好まれるようになってきており、標準化された退院プロトコールにリバーロキサバンを含めるよう各施設を後押ししています。デジタルヘルスツールは、特に高齢の患者や多剤併用患者に対する投与リマインダーや有害事象の追跡を統合することで、アドヒアランスをさらに向上させています。さらに、脳卒中予防における集学的ケアパスにはNOACが日常的に含まれるようになり、リバーロキサバンにとって好ましい環境が整いつつあります。米国心臓協会（AHA）、欧州心臓病学会（ESC）などによる臨床ガイドラインの更新は、NOACを支持し続けており、処方者の信頼を強めています。リバーロキサバンの多用途性により、治療への慣性が薄れ、患者中心の治療が高まるにつれ、抗凝固療法の補助薬市場や新興市場でシェアを獲得することができます。

リバーロキサバン市場の成長はいくつかの要因によって牽引される...

リバーロキサバンの世界市場は、臨床需要、人口動態の変化、医療システムの採用パターンによって拡大しています。高齢化社会における心房細動、静脈血栓塞栓症、慢性心血管病の有病率の増加が主な成長要因です。ワルファリンよりもNOACの方が、投与が容易で、安全性プロファイルが改善され、INRモニタリングが不要になるため、嗜好性が高まっており、市場浸透が加速しています。PAD、ACS、腫瘍関連血栓症などの新たな適応症への拡大が、市場の可能性をさらに引き出しています。進行中の臨床試験と適応拡大が治療の多様化を支えています。特にアジア太平洋とラテンアメリカでは、新興市場における規制当局の承認と償還制度の改善により、患者へのアクセスが拡大しています。特許切れに伴う費用対効果の高いジェネリック医薬品の開発は、特に公的ヘルスケアシステムにおいて処方量の増加をもたらします。アドヒアランスアプリやデジタルモニタリングプラットフォームのような技術統合は、患者の転帰を改善し、長期的な治療継続を支援しています。進化する臨床ガイドラインと実世界のエビデンスに支えられた医師の嗜好は、病院でも外来でもリバーロキサバンを支持し続けています。これらのダイナミクスにより、リバーロキサバンは長期的かつ世界的に意義のある抗凝固療法として、使用事例が増加しています。

セグメント

適応症（心房細動、深部静脈血栓症、肺塞栓症、静脈血栓塞栓症予防、その他の適応症）、剤形（錠剤、懸濁液）、患者タイプ（成人、小児）、流通チャネル（病院・クリニック、小売薬局、オンライン薬局）

調査対象企業の例（注目の41社）

• Aarti Pharmalabs Ltd.
• Actoverco Pharmaceutical Co.
• Aurobindo Pharma Ltd.
• Bayer AG
• Celix Pharma Ltd.
• Cohance Lifesciences Ltd.
• Dr. Reddy's Laboratories Ltd.
• Egis Pharmaceuticals PLC
• Glenmark Pharmaceuticals Ltd.
• Grindeks
• Inke S.A.
• Janssen Pharmaceuticals, Inc.
• LGM Pharma
• Lupin Limited
• Metrochem API Pvt. Ltd.
• Moehs Iberica S.L.
• Polpharma
• Rochem International Inc.
• Suanfarma
• Taro Pharmaceutical Industries

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Rivaroxaban Market to Reach US$22.4 Billion by 2030

The global market for Rivaroxaban estimated at US$16.3 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Atrial Fibrillation Indication, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$9.0 Billion by the end of the analysis period. Growth in the Deep Vein Thrombosis Indication segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 9.0% CAGR

The Rivaroxaban market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global “Rivaroxaban” Market - Key Trends & Drivers Summarized

Why Is Rivaroxaban Emerging as a Cornerstone in Anticoagulant Therapy?

Rivaroxaban, an oral anticoagulant belonging to the class of direct Factor Xa inhibitors, is revolutionizing the treatment and prevention of thromboembolic disorders. Developed as a more convenient alternative to traditional vitamin K antagonists like warfarin, Rivaroxaban provides predictable pharmacokinetics, fixed dosing, and minimal dietary or drug interactions, significantly improving patient adherence. It is widely used for indications such as stroke prevention in non-valvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and prophylaxis following orthopedic surgeries. The global aging population and rising incidence of cardiovascular diseases have drastically expanded the eligible patient pool. Furthermore, increased awareness of atrial fibrillation and its complications has led to earlier diagnoses and longer-term anticoagulation needs. Real-world evidence continues to reinforce Rivaroxaban’s clinical efficacy and safety, while ongoing head-to-head studies demonstrate favorable outcomes compared to other NOACs (non-vitamin K antagonist oral anticoagulants). The simplicity of use-no routine coagulation monitoring-and reduced risk of intracranial bleeding versus warfarin, make it a preferred choice among clinicians. Additionally, the convenience of once-daily dosing distinguishes it from certain competitors that require twice-daily regimens, supporting better compliance in long-term use cases.

How Are Patent Lifecycles and Generics Impacting the Market Structure?

As Rivaroxaban approaches patent expiry in major markets, the competitive landscape is undergoing a significant transformation. Branded versions, such as Xarelto® (developed by Bayer and marketed with Johnson & Johnson), have enjoyed exclusivity in high-value territories for years. However, the impending and ongoing entry of generic formulations is set to disrupt pricing dynamics and increase accessibility. Manufacturers in countries like India, China, and Brazil are preparing for expanded generic production to capitalize on newly opened markets. The introduction of bioequivalent generics is expected to lower treatment costs, particularly in cost-sensitive public health systems. Regulatory bodies such as the FDA and EMA have established fast-track processes for high-priority generics, accelerating their launch timelines. While this benefits patients and payers, it presents challenges for branded manufacturers in maintaining market share. In response, originator companies are investing in extended indications, fixed-dose combination therapies, and digital patient support platforms. Moreover, evolving reimbursement models in the US, EU, and APAC regions are creating tiered pricing strategies, forcing companies to align marketing and distribution efforts by geography and payer structure. The interplay between innovation lifecycle management and generic competition will shape the market’s pricing elasticity and volume growth.

Which Clinical Trends and Therapeutic Expansions Are Enhancing Market Potential?

Rivaroxaban’s role is expanding beyond its core indications into a broader set of cardiovascular and thromboembolic conditions. Recent approvals and trials have highlighted its use in secondary prevention of acute coronary syndrome (ACS) and peripheral artery disease (PAD), particularly in patients with coexisting conditions like diabetes or renal dysfunction. Emerging evidence supports Rivaroxaban’s utility in cancer-associated thrombosis, where conventional anticoagulants pose higher bleeding risks. Several Phase III trials are also exploring Rivaroxaban in conjunction with antiplatelet agents to prevent cardiovascular events in high-risk patients. The growing preference for oral over parenteral anticoagulation in hospital-to-home transitions is pushing institutions to include Rivaroxaban in standardized discharge protocols. Digital health tools are further enhancing adherence by integrating dosing reminders and adverse event tracking, especially for elderly or polymedicated patients. Additionally, multidisciplinary care pathways in stroke prevention now routinely include NOACs, creating a favorable environment for Rivaroxaban. Clinical guideline updates from the American Heart Association (AHA), European Society of Cardiology (ESC), and others continue to endorse NOACs, reinforcing prescriber confidence. As therapeutic inertia diminishes and patient-centered care rises, Rivaroxaban’s versatility positions it to capture share in adjunct and emerging anticoagulation markets.

The Growth in the Rivaroxaban Market Is Driven by Several Factors...

The global rivaroxaban market is expanding due to clinical demand, demographic shifts, and health system adoption patterns. Increasing prevalence of atrial fibrillation, venous thromboembolism, and chronic cardiovascular disease in aging populations is a primary growth driver. Rising preference for NOACs over warfarin-due to ease of administration, improved safety profiles, and elimination of INR monitoring-is accelerating market penetration. Expansion into new indications, such as PAD, ACS, and oncology-related thrombosis, is further unlocking market potential. Ongoing clinical trials and label extensions are supporting therapeutic diversification. Regulatory approvals in emerging markets and improved reimbursement coverage are broadening patient access, particularly in Asia-Pacific and Latin America. The development of cost-effective generics following patent expirations is poised to increase prescription volume, particularly in public healthcare systems. Technological integrations like adherence apps and digital monitoring platforms are improving patient outcomes and supporting long-term therapy continuation. Physician preference, supported by evolving clinical guidelines and real-world evidence, continues to favor Rivaroxaban in hospital and outpatient settings alike. Together, these dynamics position Rivaroxaban as a long-term, globally relevant anticoagulation therapy across a growing range of use cases.

SCOPE OF STUDY:

The report analyzes the Rivaroxaban market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, Other Indications); Formulation (Tablets, Suspension); Patient Type (Adults, Pediatrics); Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Aarti Pharmalabs Ltd.
• Actoverco Pharmaceutical Co.
• Aurobindo Pharma Ltd.
• Bayer AG
• Celix Pharma Ltd.
• Cohance Lifesciences Ltd.
• Dr. Reddy's Laboratories Ltd.
• Egis Pharmaceuticals PLC
• Glenmark Pharmaceuticals Ltd.
• Grindeks
• Inke S.A.
• Janssen Pharmaceuticals, Inc.
• LGM Pharma
• Lupin Limited
• Metrochem API Pvt. Ltd.
• Moehs Iberica S.L.
• Polpharma
• Rochem International Inc.
• Suanfarma
• Taro Pharmaceutical Industries

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Rivaroxaban - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Thromboembolic Disorders Propels Demand for Oral Anticoagulants Like Rivaroxaban
  • Aging Global Population and Increased Prevalence of Atrial Fibrillation Sustain Long-Term Market Growth
  • Preference for Direct Oral Anticoagulants (DOACs) Over Warfarin Strengthens Business Case for Rivaroxaban
  • Expanding Off-Label Usage in Stroke Prevention and Post-Surgical Care Throws the Spotlight on Therapeutic Versatility
  • Improved Patient Adherence Due to Fixed Dosing and No Routine Monitoring Drives Clinical Adoption
  • Guideline Updates Favoring DOACs in Cardiovascular Treatment Regimens Accelerate Prescriptions
  • Patent Expiries in Key Markets Generate Competitive Price Pressures and Generic Entry Challenges
  • Rising Healthcare Expenditures and Reimbursement Coverage Expand Access to Advanced Anticoagulant Therapies
  • Clinical Trials Supporting Use in Cancer-Associated Thrombosis Fuel Demand in Oncology Segment
  • Adverse Event Surveillance and Bleeding Risk Concerns Create Opportunities for Safer Formulations
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Rivaroxaban Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Rivaroxaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Pulmonary Embolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Prophylaxis of Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Prophylaxis of Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Prophylaxis of Venous Thromboembolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• JAPAN
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• CHINA
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• EUROPE
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Rivaroxaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• FRANCE
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• GERMANY
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Rivaroxaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• INDIA
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Rivaroxaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Rivaroxaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
• AFRICA
  • Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030

IV. COMPETITION